A003090 Stock Overview
Engages in the manufacture and sale of pharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Daewoong Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩27,450.00 |
| 52 Week High | ₩28,100.00 |
| 52 Week Low | ₩15,050.00 |
| Beta | 1.26 |
| 1 Month Change | 34.89% |
| 3 Month Change | 37.87% |
| 1 Year Change | 68.10% |
| 3 Year Change | -5.83% |
| 5 Year Change | 12.50% |
| Change since IPO | 1,162.97% |
Recent News & Updates
A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)
May 29
Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture
Mar 14Recent updates
A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)
May 29Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture
Mar 14These 4 Measures Indicate That Daewoong (KRX:003090) Is Using Debt Extensively
Nov 11Daewoong Co., Ltd. (KRX:003090) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 01Daewoong Co., Ltd.'s (KRX:003090) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 14Is Daewoong (KRX:003090) Using Too Much Debt?
Jul 04Does Daewoong (KRX:003090) Have A Healthy Balance Sheet?
Apr 02With EPS Growth And More, Daewoong (KRX:003090) Is Interesting
Apr 13A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)
Mar 29Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Mar 14Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly
Feb 21The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders
Jan 31
Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?
Dec 04Shareholder Returns
| A003090 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 39.2% | 3.5% | 3.9% |
| 1Y | 68.1% | 5.7% | -1.3% |
Return vs Industry: A003090 exceeded the KR Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: A003090 exceeded the KR Market which returned -1.3% over the past year.
Price Volatility
| A003090 volatility | |
|---|---|
| A003090 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.4% |
| 10% least volatile stocks in KR Market | 3.0% |
Stable Share Price: A003090's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A003090's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 356 | Yeong-Hwan Yoon | www.daewoongholdings.com |
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd.
Daewoong Co., Ltd. Fundamentals Summary
| A003090 fundamental statistics | |
|---|---|
| Market cap | ₩1.12t |
| Earnings (TTM) | ₩62.94b |
| Revenue (TTM) | ₩1.97t |
Is A003090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003090 income statement (TTM) | |
|---|---|
| Revenue | ₩1.97t |
| Cost of Revenue | ₩902.92b |
| Gross Profit | ₩1.07t |
| Other Expenses | ₩1.01t |
| Earnings | ₩62.94b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.54k |
| Gross Margin | 54.27% |
| Net Profit Margin | 3.19% |
| Debt/Equity Ratio | 48.2% |
How did A003090 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 17:05 |
| End of Day Share Price | 2025/06/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daewoong Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyonseok Kim | CLSA |
| Bora Chung | Daishin Securities Co. Ltd. |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |